再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

交易中 06-16 14:41:42 EDT

17.81

+0.08

+0.45%

最高17.96	最低17.62	成交量20.43万
今开17.87	昨收17.73	日振幅1.90%
总市值20.01亿	流通市值19.48亿	总股本1.12亿
成交额363.83万	换手率0.19%	流通股本1.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":17.81,"timestamp":1781635294659,"preClose":17.73,"halted":0,"volume":204279,"delay":0,"changeRate":0.004512126339537411,"floatShares":109371942,"shares":112353700,"eps":-1.6209,"marketStatus":"交易中","change":0.08,"latestTime":"06-16 14:41:42 EDT","open":17.87,"high":17.9569,"low":17.62,"amount":3638252.5014270004,"amplitude":0.019002,"askPrice":17.82,"askSize":34,"bidPrice":17.8,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-1.6209,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1781640000000},"marketStatusCode":2,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":17.73,"preHourTrading":{"tag":"盘前","latestPrice":18.1023,"preClose":17.73,"latestTime":"09:24 EDT","volume":348,"amount":6290.25834,"timestamp":1781616252179,"change":0.3723,"changeRate":0.020998,"amplitude":0.027073},"postHourTrading":{"tag":"盘后","latestPrice":17.73,"preClose":17.73,"latestTime":"18:07 EDT","volume":7521,"amount":133349.13,"timestamp":1781561264781,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.232113,"impliedVol":0.4671,"impliedVolPercentile":0.2112},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2642144385","title":"港股异动 | 再鼎医药(09688)涨超4% 精神分裂创新药凯捷乐®上市 宫颈癌新药在华获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2642144385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642144385?lang=zh_cn&edition=full","pubTime":"2026-06-10 14:46","pubTimestamp":1781074008,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药涨超4%，截至发稿，涨4.06%，报13.07港元，成交额1.56亿港元。当天，该药在首都医科大学附属北京安定医院开出全国首张处方，并于同日惠及全国30余个城市、近50家医院的精神分裂症患者。此外，再鼎医药日前宣布，国家药品监督管理局已批准缇乐的生物制品上市许可申请，用于治疗化疗期间或之后出现进展的复发或转移性宫颈癌成人患者。维替索妥尤单抗在全球3期innovaTV301临床研究中展现出了显著的统计学意义总生存获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4526","06978","159992","BK1574","BK1161","BK4548","09688","BK1588","BK4531","BK4585","IPOS","LU2488822045.USD","BK4139","BK4588","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640020489","title":"再鼎医药(09688)授出5000份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2640020489","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640020489?lang=zh_cn&edition=full","pubTime":"2026-06-03 21:25","pubTimestamp":1780493128,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，公司于2026年6月1日(美国东部时间)根据2024年股权激励计划授出5000份受限制股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4588","ZLAB","BK1161","BK4526","BK1574","BK4548","BK4585","09688","LU2488822045.USD","BK4139","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638582374","title":"547万美元年薪总裁匆匆离场，再鼎医药发生了什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2638582374","media":"华夏时报网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638582374?lang=zh_cn&edition=full","pubTime":"2026-05-25 11:44","pubTimestamp":1779680649,"startTime":"0","endTime":"0","summary":"5月22日，再鼎医药（09688.HK）一则公告引发市场高度关注——公司总裁兼首席运营官JoshSmiley将不再担任现任职务，自5月18日起生效，最后任职日期为5月22日。颇为耐人寻味的是，从董事会作出决定到这位“二把手”正式离场，仅间隔4天。公告同时提及，Smiley需签署一份“常规的解除协议”后方可获得遣散补偿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605253747976870.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605253747976870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4548","09688","BK4526","BK4585","BK4588","BK1161","ZLAB","LU2488822045.USD","BK4531","BK1588","BK4139","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637653033","title":"再鼎医药(09688)：Josh Smiley不再担任公司总裁兼首席运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2637653033","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637653033?lang=zh_cn&edition=full","pubTime":"2026-05-22 08:25","pubTimestamp":1779409550,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于2026年5月21日(美国东部时间)╱2026年5月22日(上海及香港时间)向美国证券交易委员会(SEC)递交了一份表格8-K，有关本公司董事会决定 Josh Smiley 先生将不再担任本公司总裁兼首席运营官，自2026年5月18 日起生效，其在本公司的最后任职日期为2026年5月22日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"再鼎医药(09688)：Josh Smiley不再担任公司总裁兼首席运营官","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1588","BK4548","ZLAB","BK4585","BK4526","09688","BK4531","BK4139","BK1161","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635033220","title":"再鼎医药(ZLAB)逆市上涨1.52% zoci近日获美国FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2635033220","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635033220?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:40","pubTimestamp":1778856000,"startTime":"0","endTime":"0","summary":"金吾财讯 |再鼎医药 逆市上涨1.52%，最新报20.64美元，成交额774.69万美元。消息面上，再鼎医药官微日前宣布，美国食品药品监督管理局已授予具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。此外，高盛新近披露，已于5月8日以每股均价15.09港元场外增持再鼎医药545.57万股H股股份，价值约8,232.65万港元。增持后，高盛最新持股数目为7,070.61万股股份，好仓比例由5.75%升至6.23%。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/NWIzNTQyNTc0Mjc1MDI=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWIzNTQyNTc0Mjc1MDI=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300518","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK1588","BK1574","BK4548","BK4588","09688","LABU","ZLAB","BK4531","BK4526","BK1161","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635700344","title":"港股异动 | 再鼎医药(09688)尾盘涨超5% zoci获FDA快速通道资格认定 用于治疗肺外神经内分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2635700344","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635700344?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:50","pubTimestamp":1778831448,"startTime":"0","endTime":"0","summary":"再鼎医药(09688)尾盘涨超5%，截至发稿，涨4.89%，报16.1港元，成交额2.47亿港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260515/20260515155119_66712.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260515/20260515155119_66712.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4548","LU2488822045.USD","BK4588","ZLAB","BK4139","VXUS","BK4531","BK1588","BK1574","BK4526","BK4585","LABU","BK1161","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634299314","title":"再鼎医药(09688)：授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2634299314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634299314?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:34","pubTimestamp":1778574847,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于授出日期根据2024年股权激励计划授出13.68万份购股权(以美国存托股份计)、7.53万份受限制股份单位(以美国存托股份计)。所授出购股权涉及的相关股份数目：1,368,190;所授出受限制股份单位涉及的相关股份数目：752,880。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4526","BK4531","BK4139","BK1574","ZLAB","BK4585","BK1161","09688","BK4548","LU2488822045.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634250452","title":"港股异动 | 再鼎医药(09688)早盘涨超5% zoci获FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2634250452","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634250452?lang=zh_cn&edition=full","pubTime":"2026-05-12 10:55","pubTimestamp":1778554548,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药早盘涨超5%，截至发稿，涨2.38%，报15.49港元，成交额7370.89万港元。消息面上，5月11日，据再鼎医药官微消息，公司宣布，美国食品药品监督管理局已授予具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 再鼎医药(09688)早盘涨超5% zoci获FDA快速通道资格认定","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","ZLAB","BK1119","BK4531","BK1574","BK4526","BK4548","BK4139","BK4588","LU2488822045.USD","BK1161","09688","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109751999","title":"异动解读 | 再鼎医药盘中大涨10.56%，自研药物Zoci获FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1109751999","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109751999?lang=zh_cn&edition=full","pubTime":"2026-05-11 23:44","pubTimestamp":1778514241,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中股价大幅上涨10.56%，引起了市场的广泛关注。该疾病为侵袭性强、预后差的恶性肿瘤，目前全球尚无获批的靶向疗法与标准治疗方案，存在巨大的未满足医疗需求。此外，在2026年AACR年会上公布的Ib/II期注册研究数据显示，Zoci用于多线治疗失败的epNEC患者，客观缓解率达到38.2%，且安全性可控。目前，Zoci针对epNEC的临床项目正在推进注册，并已与药监部门沟通注册计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162641298","title":"异动解读 | 再鼎医药自研药物Zoci获FDA快速通道资格，盘前大涨6.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162641298","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162641298?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:05","pubTimestamp":1778501135,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘前股价大涨6.45%，引起了市场的广泛关注。据悉，epNECs为侵袭性强、预后差的恶性肿瘤，全球约10万人患病，目前无获批靶向疗法与标准治疗方案，存在巨大未满足医疗需求。此外，2026年AACR年会公布的Ib/II期注册研究显示，Zoci用于多线治疗失败的epNEC患者，客观缓解率达38.2%，且安全性可控。目前Zoci的epNEC临床项目正推进注册，已与药监部门沟通注册计划。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285739","title":"再鼎医药(ZLAB)自研药物Zoci获美国FDA授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285739","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634285739?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:36","pubTimestamp":1778499399,"startTime":"0","endTime":"0","summary":"据悉，epNECs为侵袭性强、预后差的恶性肿瘤，全球约10万人患病，无获批靶向疗法与标准治疗方案，存在巨大未满足医疗需求。此前2025年5月，Zoci已获FDA快速通道资格，用于广泛期小细胞肺癌治疗。此外，2026年AACR年会公布的Ib/II期注册研究显示，Zoci用于多线治疗失败的epNEC患者，客观缓解率达38.2%，且安全性可控，仅中性粒细胞减少为唯一≥3级且多例出现的治疗相关不良反应。目前Zoci的epNEC临床项目正推进注册，已与药监部门沟通注册计划。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300251","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","09688","BK4139","LU2488822045.USD","BK4588","BK1161","BK1574","BK4548","BK4531","BK1588","ZLAB","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634477601","title":"大行评级丨大摩：下调再鼎医药港股目标价至19港元，维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634477601","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634477601?lang=zh_cn&edition=full","pubTime":"2026-05-11 14:07","pubTimestamp":1778479621,"startTime":"0","endTime":"0","summary":"摩根士丹利发表研报，更新对再鼎医药的风险回报评估，将港股目标价由19.5港元下调至19港元，维持“增持”评级。该行根据首季趋势调整了则乐(Zejula)及瑞普替尼(repotrectinib)的销售预测，导致2026年至2028年的收入预测下调5%。大摩预测再鼎医药2026年收入为4.88亿美元，研发开支2.34亿美元，销售开支2.93亿美元；将2026年至2028年每股盈利亏损预测由0.16、0.10及0.07美元，修订为0.18、0.12及0.08美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260511/32214732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["VXUS","09688","ZLAB","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634247289","title":"大行评级丨中银国际：再鼎医药首季业绩疲弱，H股目标价大幅下调至17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634247289","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634247289?lang=zh_cn&edition=full","pubTime":"2026-05-11 13:37","pubTimestamp":1778477821,"startTime":"0","endTime":"0","summary":"中银国际发表研报指，再鼎医药首季业绩疲弱，收入同比下降6%至9960万美元，低于市场预期9%，主要受到则乐降幅超预期以及艾加莫德医保降价影响。持续加大的研发投入导致净亏损扩大至5100万美元。管理层预计2026年剩余时间收入将逐渐改善，但全年增长仍将受压，恢复增长预计要到2027年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260511/32214697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["ZLAB","09688","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179031134","title":"异动解读 | 财报不及预期叠加核心产品收入下滑，再鼎医药盘中大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179031134","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179031134?lang=zh_cn&edition=full","pubTime":"2026-05-09 00:28","pubTimestamp":1778257718,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大跌5.08%，引发了市场的广泛关注。消息面上，公司此前公布的2026年第一季度财报显示，总收入为9960万美元，同比下滑6%，产品收入净额同比下降10%。具体来看，公司赖以起家的核心产品则乐受集采后医院用药模式变化影响，收入出现显著下降；另一款产品卫伟迦也因医保续约降价而出现小幅下滑。此外，公司近期宣布由王轶喆博士负责商业化工作，商业化团队换帅的时点与业绩波动叠加，引发了市场对于公司治理是否稳定的疑虑。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633699433","title":"创新管线即将步入密集催化阶段，探寻再鼎医药（09688）否极泰来的“三张底牌”","url":"https://stock-news.laohu8.com/highlight/detail?id=2633699433","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633699433?lang=zh_cn&edition=full","pubTime":"2026-05-08 16:07","pubTimestamp":1778227661,"startTime":"0","endTime":"0","summary":"5月7日，再鼎医药交出2026年一季报：总收入9960万美元，同比下滑6%，产品收入净额同比下降10%。乍看之下，这是一份“不及预期”的成绩单。但从2025年下半年开始，再鼎的内部重心已经发生了根本性转移。未来一年管线“催化剂密集”如果说商业化是再鼎的“底盘”，那么全球研发管线就是它的“发动机”。总结来看，当前再鼎的股价大跌之后，依旧握有三张清晰的底牌：第一张牌：全球管线的“硬核数据”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4526","BK4531","BK4139","BK1574","ZLAB","BK4585","BK1161","09688","BK4548","LU2488822045.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633147905","title":"再鼎医药(09688)第一季度总收入为9960万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633147905","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633147905?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:45","pubTimestamp":1778157937,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药 发布公告，2026年第一季度总收入为9960万美元，2025年同期为1.065亿美元，同比下降6%，2026年第一季度产品收入净额为9560万美元，2025年同期为1.057亿美元，同比下降10%，按固定汇率计算同比下降12%。2026年第一季度亏损净额为5100万美元，归属于普通股股东的每股普通股亏损为0.05美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK1161","BK4531","ZLAB","BK4585","BK1588","BK4548","BK4588","09688","BK1574","BK4139","BK4526"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1170693892","title":"财报前瞻｜再鼎医药营收预计下滑0.50%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1170693892","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170693892?lang=zh_cn&edition=full","pubTime":"2026-04-30 15:32","pubTimestamp":1777534378,"startTime":"0","endTime":"0","summary":"再鼎医药将于2026年05月07日美股盘前发布最新季度财报，市场聚焦营收变动、利润曲线与关键管线推进节奏。市场一致预期本季度再鼎医药营收为1.13亿美元，同比下降0.50%；调整后每股收益预计为-0.50美元，同比改善9.62%。结合2026年05月07日的财报披露节点，机构普遍将本季度检验点聚焦于收入韧性、费用效率与DLL3临床推进的具体说明，整体倾向认为在基本面催化与管线价值共振下，估值具备进一步重估空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜再鼎医药营收预计下滑0.50%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630589301","title":"再鼎医药(ZLAB)逆势上涨2.66% 机构指Zoci数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2630589301","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630589301?lang=zh_cn&edition=full","pubTime":"2026-04-28 23:20","pubTimestamp":1777389610,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药 逆势上涨2.66%，最新报22.44美元，成交额309.77万美元。机构维持2026年和2027年盈利预测不变，维持跑赢行业评级，且由于Zoci数据积极，机构上调Zoci未来销售峰值，基于DCF模型，上调H股/US股目标价15%/15%至22.0港元/28.4美元，较当前股价有16.8%/24.2%上行空间。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299809","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","LU2488822045.USD","BK1161","ZLAB","09688","BK1574","BK4139","BK4548","BK4588","BK4531","BK4585","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629688951","title":"再鼎医药(09688.HK)：5月7日董事会审议及批准第一季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2629688951","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629688951?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:47","pubTimestamp":1776934021,"startTime":"0","endTime":"0","summary":"格隆汇4月23日丨再鼎医药公布，董事会审核委员会将于2026年5月7日(星期四)审议及批准根据美国公认会计准则及美国证券交易委员会的适用规则编制的公司及其附属公司截至2026年3月31日止三个月的未经审核季度业绩及其发布。　　在第一季度业绩获批准及发布后，公司管理层计划在2026年5月7日上午8:00/2026年5月7日下午8:00举行现场业绩电话会议及网络直播，以讨论第一季度业绩并回答提问。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260423/32167897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4548","09688","BK4526","BK4585","BK4588","BK1161","ZLAB","LU2488822045.USD","BK4531","BK1588","BK4139","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629303730","title":"再鼎医药(ZLAB)盘初跌超3% 此前录得6连阳累计涨幅达22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629303730","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629303730?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:04","pubTimestamp":1776780260,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药(ZLAB)盘初股价出现回调，暂报24.485美元，跌幅3.03%。该股此前录得6连阳，累计涨幅达22%。四月至今累计涨幅超30%。消息面上，公司近日公布了ZL-1503临床前研究的最新数据，数据表明公司自主研发的这款IL-13/IL-31Rα双特异性抗体可能持续抑制特应性疾病引起的剧烈瘙痒和炎症。机构评级方面，坎托·菲茨杰拉德分析师Li Watsek维持再鼎医药“买入”评级，维持目标价37美元；摩根大通分析师Anupam Rama维持再鼎医药“买入”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/ZjY1NDI1NzQxNDM1Mw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZjY1NDI1NzQxNDM1Mw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299518","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","09688","BK4139","BK4531","BK4548","ZLAB","BK1588","BK4588","LU2488822045.USD","BK1574","BK4526","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0758},{"period":"1month","weight":-0.1389},{"period":"3month","weight":-0.0678},{"period":"6month","weight":0.0296},{"period":"1year","weight":-0.5676},{"period":"ytd","weight":0.0051}],"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.1253},{"period":"6month","weight":0.1243},{"period":"1year","weight":0.2644},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.085823},{"month":2,"riseRate":0.555556,"avgChangeRate":0.030708},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.076257},{"month":4,"riseRate":0.444444,"avgChangeRate":0.02394},{"month":5,"riseRate":0.444444,"avgChangeRate":0.004882},{"month":6,"riseRate":0.555556,"avgChangeRate":0.067303},{"month":7,"riseRate":0.5,"avgChangeRate":0.004927},{"month":8,"riseRate":0.625,"avgChangeRate":0.000651},{"month":9,"riseRate":0.375,"avgChangeRate":-0.055585},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.047464},{"month":11,"riseRate":0.555556,"avgChangeRate":0.101421},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.029495}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}